Novartis says top R&D executives no longer at Avexis unit after test data manipulation
August 14, 2019 at 11:11 AM EDT
Novartis said on Wednesday the two top research & development executives at its Avexis unit were no longer at the company after some data from early testing of Avexis's more than $2-million gene therapy Zolgensma was manipulated.